LMATHealthcare · Medical Instruments & SuppliesThe 8 Wall Street analysts covering LeMaitre Vascular, Inc. hold a median 12-month price target of $100 — +23.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 14 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores LeMaitre Vascular, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Revisions (41): Analysts have, on balance, been cutting their forecasts.
Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LMAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $104 → $94 |
| 3 June 2026 | Barrington Research | Maintains | Outperform | $120 |
| 3 June 2026 | Barrington Research | Maintains | Outperform | — |
| 6 May 2026 | Barrington Research | Maintains | Outperform | — |
| 6 May 2026 | Citizens | Maintains | Market Outperform | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 26 Feb 2026 | Citizens | Maintains | Market Outperform | — |
| 26 Feb 2026 | Roth Capital | Reiterates | Buy | — |
| 26 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 20 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 7 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Nov 2025 | Roth Capital | Reinstates | Buy | $108 |
| 15 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 6 Aug 2025 | Barrington Research | Upgrade | Outperform | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Neutral | — |
| 22 July 2025 | Barrington Research | Reiterates | Market Perform | — |
| 28 Feb 2025 | Barrington Research | Downgrade | Market Perform | — |
| 28 Feb 2025 | Citizens Capital Markets | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LMAT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, LeMaitre Vascular, Inc. returned −11.6% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 27% of US stocks
Cheaper than 18% of US stocks
Cheaper than 23% of US stocks
Cheaper than 15% of US stocks
Higher than 51% of US stocks
Higher than 61% of US stocks
Higher than 84% of US stocks
Higher than 87% of US stocks
Higher than 86% of US stocks
Higher than 77% of US stocks
Higher than 86% of US stocks
Higher than 29% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LeMaitre Vascular, Inc. has a market value of $1.8B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $262.4M. The latest quarter grew 9.6% year on year.
Net income over the same four quarters: $65.7M, a 25.0% net margin.
Diluted earnings per share, trailing twelve months: $2.85.
Free cash flow in the twelve months to 30 June 2026: $73.8M.
LeMaitre Vascular, Inc. spent $20.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 28.2×; forward P/E: 25.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.24%, paying out 31% of earnings.
LeMaitre Vascular, Inc. employs 646 people — $406K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LeMaitre Vascular, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research article compares LeMaitre Vascular (LMAT) with Phibro Animal Health (PAHC) as potential value investments within the Medical - Products sector, examining which stock is more attractive to value investors.
Why it matters — LMAT watchers may gain insight into how the company is being evaluated against a sector peer from a value-investing perspective.
LeMaitre Vascular announced that management will participate in three upcoming investor conferences in September. The announcement was made on August 27, 2026.
Why it matters — LMAT watchers may be interested because management participation at investor conferences could provide opportunities for company updates and engagement with the investment community.
A Seeking Alpha article provides a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers, noting companies that changed their dividends and those with upcoming ex-dividend dates.
Why it matters — LMAT watchers may find the update relevant if LeMaitre Vascular is mentioned among the dividend-paying companies tracked in these categories.
Zacks Investment Research published a piece comparing GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT) to determine which Medical Products stock presents the better value opportunity for investors at this time.
Why it matters — The comparison places LeMaitre Vascular's valuation and investment profile directly against a major industry peer, offering context for how the company is perceived in the medical-products sector.
LeMaitre Vascular shares fell 31% after the company cut guidance by $0.02 due to currency headwinds, export blockages, and tissue shortages, though organic sales grew 10% and margins reached record highs.
Why it matters — An LMAT watcher would care because the pullback is attributed to temporary factors rather than weakening demand, while Artegraft continues to drive margin expansion and international growth.
The 8 Wall Street analysts covering LeMaitre Vascular, Inc. have a median 12-month price target of $100, with estimates ranging from $81 to $132. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering LeMaitre Vascular, Inc., 4 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeMaitre Vascular, Inc. 69 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, LeMaitre Vascular, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +23.8% from the last close, and Ticker Nerd's factor model ranks LeMaitre Vascular, Inc. 69 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LeMaitre Vascular, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $132 over the next 12 months.
LeMaitre Vascular, Inc. returned -11.6% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease.
The most recent item we track (Zacks Investment Research, 2 Sept 2026): "PAHC or LMAT: Which Is the Better Value Stock Right Now?". A Zacks Investment Research article compares LeMaitre Vascular (LMAT) with Phibro Animal Health (PAHC) as potential value investments within the Medical - Products sector, examining which stock is more attractive to value investors.
LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease. The company develops, manufactures, and markets a specialized portfolio that includes biologic patches, vascular grafts, catheters, carotid shunts, valvulotomes, radiopaque marking tape, and other disposable and implantable tools used to repair blood vessels and support bypass, access, and clot-removal procedures. LeMaitre Vascular also provides human tissue cryopreservation services for implantation, adding a complementary service component to its device business. Its offerings are used by vascular surgeons and related specialists in hospitals and surgical settings, giving the company a focused role in a niche segment of the broader medical technology market.
CEO Mr. George W. LeMaitre · 646 employees · United States · https://www.lemaitre.com
